Author response to: Comment on: Randomized clinical trial on D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in patients undergoing gastrectomy for cancer (DCGC01 study).

This document is a response to a comment on a randomized clinical trial comparing two surgical techniques for gastrectomy in cancer patients. The authors provide evidence for the effectiveness of D2 lymphadenectomy plus complete mesogastric excision (CME) in reducing surgical risk and improving oncological outcomes. They address concerns about surgeon proficiency, potential bias in the study, and the role of neoadjuvant chemotherapy. The authors conclude that D2 + CME shows potential benefits but acknowledge the need for further evaluation, particularly in patients receiving neoadjuvant chemotherapy. [Extracted from the article]